CANCER BIOLOGICS MARKET ANALYSIS

Regional Analysis

Global Cancer Biologics Market Regional Analysis

North America is expected to account for highest market share in the global cancer biologics market, owing to increasing prevalence of cancer, among people in North America. For instance, in 2019, in the U.S, according to the American Cancer Society’s (ACS), around 1,762,450 new cancer cases were diagnosed, and 606,880 new cancer deaths were reported.

Furthermore, increasing drug approvals for the treatment of metastatic merkel cell carcinoma (MCC) by the company is one of the factors that is driving the global cancer biologic market growth. For instance, in 2018, pembrolizumab received approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients suffering from metastatic Merkel cell carcinoma (MCC).

Europe is expected to account for second highest market share in the global cancer biologics market, owing to increasing prevalence of cancer in Europe region. For instance, in 2018, around 3.9 million of cancer with new cases excluding non-melanoma skin cancer, and 1.9 million death from cancer were reported by the International Agency for Research on Cancer (IARC), in collaboration with the European Network of Cancer Registries (ENCR, as well as the European Commission’s Joint Research Centre (JRC).

Moreover, Asia Pacific is expected to exhibit CAGR over the forecast period due to the increasing approval of drugs by regulatory bodies for the treatment of Hodgkin's disease (blood cancer) by the company. For instance, in 2018, National Medical Products Administration (NMPA) of China approved Sintilimab injection, which is sold under the brand name Tyvyt, and was jointly announced by Innovent Biologics, Inc. and Eli Lilly and Company. Sintilimab injection is used for the treatment of Hodgkin's disease (blood cancer), and is fully human IgG4 monoclonal antibody.